Tue, Jul 22, 2014, 1:51 PM EDT - U.S. Markets close in 2 hrs 9 mins

Recent

% | $
Click the to save as a favorite.

PolyMedix, Inc. Message Board

  • fearingsf fearingsf Dec 13, 2012 2:09 PM Flag

    Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

    NASDAQ: DRTX) today announced preliminary, top-line results for its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

    Preliminary top-line data show that dalbavancin achieved its primary endpoint of non-inferiority (10% non-inferiority margin) at 48-72 hours after initiation of therapy, as determined by the cessation of spread of the lesion, as well as the resolution of fever. Researchers were comparing two intravenous (IV) doses of dalbavancin given one week apart with twice-daily vancomycin doses for 14 days. Patients randomized to the vancomycin regimen had an option to switch to oral linezolid after three days of vancomycin treatment. In addition, the key secondary endpoints were supportive of the primary endpoint.

    The DISCOVER 1 protocol was conducted pursuant to a special protocol agreement (SPA) with the U.S. Food and Drug Administration (FDA) based on the FDA's Draft Guidance for Developing Drugs for Treatment of ABSSSI. The protocol for the trial was also designed based on scientific advice provided by the European Medicines Agency (EMA). DISCOVER 1 was a randomized, double-blind, double-dummy trial conducted in 573 patients at 92 sites in the United States, Canada, and Europe comparing dalbavancin to a regimen of vancomycin and an option for oral linezolid for the treatment of ABSSSI.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 1 product, 2 indications (the second in phase1) and a $163million market cap.

      PYMX market cap = $20million.

      The major difference IMO (aside from them being in phase3).........Durata has $60mil in cash. Amazing what a secure near to mid-term financial future will do for the pps of its stock.

      • 1 Reply to mulletman99
      • Pfizer aquired Dalbavancin back in 05 when it bought Vacuron pharma. In 08 Pfizer announced that it will withdraw all marketing apps. Dureta aquired the rights in 09. Due to their toxicity, use of glycopeptide antibiotics is restricted to patients who are critically ill. Some tissues are not penetrated and they do not penetrate the cerebrospinal fluid. Brock

        Sentiment: Strong Buy

    • Dalbavancin is a second generation lipoglycopeptide antibiotic. It belongs to the same class a Vancomycin. It has a much longer half life of about 300 hours thus the initial dose and then another dose a week later. Same old problem. Resistance development. Brilacidin on the other hand is a one to three day dosing with a 17 hour half life that kills all the bacteria with little chance of resistance occuring. Really no comparison. Brock

      Sentiment: Strong Buy

 
PYMXQ
0.020.00(0.00%)Jul 22 9:52 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.